Regenicin, Inc. Share Price Other OTC
Equities
RGIN
US75887Q1022
Biotechnology & Medical Research
Sales 2021 | - | Sales 2022 | - | Capitalization | 491K 40.93M |
---|---|---|---|---|---|
Net income 2021 | - 0 | Net income 2022 | - 0 | EV / Sales 2021 | - |
Net Debt 2021 | 598K 49.86M | Net Debt 2022 | 627K 52.29M | EV / Sales 2022 | - |
P/E ratio 2021 |
-2
x | P/E ratio 2022 |
-0.71
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 79.1% |
Managers | Title | Age | Since |
---|---|---|---|
Randall McCoy
CEO | Chief Executive Officer | 74 | 15/10/15 |
John Weber
DFI | Director of Finance/CFO | 74 | 13/10/13 |
J. Nelson
CTO | Chief Tech/Sci/R&D Officer | 75 | 15/10/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Weber
DFI | Director of Finance/CFO | 74 | 13/10/13 |
Randall McCoy
CEO | Chief Executive Officer | 74 | 15/10/15 |
1st Jan change | Capi. | |
---|---|---|
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |